search
Back to results

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
AD-2101
AD-2102
AD-2101 + AD-2102
Sponsored by
Addpharma Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

19 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male between 19 and 50 years of age at the time of screening
  • Weight above 50 kg and body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2

Exclusion Criteria:

  • Clinically significant disease or history of clinically significant disease such as cardiovascular, respiratory, liver, kidney, digestive, hematologic/oncologic, endocrine, immunologic, urinary, psychiatric
  • Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery
  • A person who has a history of drug abuse
  • AST, ALT, Total bilirubin values over than 2 times of UNL at screening
  • Creatinine clearance under 80mL/min

Sites / Locations

  • Korea University Guro Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Sequence 1

Sequence 2

Sequence 3

Sequence 4

Sequence 5

Sequence 6

Arm Description

Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102

Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102

Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102

Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101

Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102

Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101

Outcomes

Primary Outcome Measures

Peak Plasma Concentration
Cmax,ss of the total ingredient of AD-2101 and AD-2102
Area under the plasma concentration versus time curve
AUCt,ss of the total ingredient of AD-2101 and AD-2102

Secondary Outcome Measures

Time to reach Cmax
Tmax,ss of the total ingredient of AD-2101 and AD-2102
Clearance
CLss/F of the total ingredient of AD-2101 and AD-2102
Bottom Plasma Concentration
Cmin,ss of the total ingredient of AD-2101 and AD-2102
Number of participants with adverse events
Incidence rate of adverse events

Full Information

First Posted
October 19, 2020
Last Updated
July 20, 2021
Sponsor
Addpharma Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04600284
Brief Title
Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102
Official Title
A Randomized, Open Label, Multiple Dose, Crossover Study to Evaluate Drug-drug Interaction of AD-2101 and AD-2102 in Healthy Male Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
November 16, 2020 (Actual)
Primary Completion Date
January 20, 2021 (Actual)
Study Completion Date
April 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Addpharma Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.
Detailed Description
To evaluate the pharmacokinetic Interaction, safety and tolerability of the combination compared with the administration of AD-2101 and AD-2102.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
Arm Title
Sequence 2
Arm Type
Experimental
Arm Description
Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
Arm Title
Sequence 3
Arm Type
Experimental
Arm Description
Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
Arm Title
Sequence 4
Arm Type
Experimental
Arm Description
Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
Arm Title
Sequence 5
Arm Type
Experimental
Arm Description
Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
Arm Title
Sequence 6
Arm Type
Experimental
Arm Description
Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
Intervention Type
Drug
Intervention Name(s)
AD-2101
Intervention Description
AD-2101 16/5mg
Intervention Type
Drug
Intervention Name(s)
AD-2102
Intervention Description
AD-2102 25mg
Intervention Type
Drug
Intervention Name(s)
AD-2101 + AD-2102
Intervention Description
AD-2101 16/5mg + AD-2102 25mg
Primary Outcome Measure Information:
Title
Peak Plasma Concentration
Description
Cmax,ss of the total ingredient of AD-2101 and AD-2102
Time Frame
pre-dose to 24 hours
Title
Area under the plasma concentration versus time curve
Description
AUCt,ss of the total ingredient of AD-2101 and AD-2102
Time Frame
pre-dose to 24 hours
Secondary Outcome Measure Information:
Title
Time to reach Cmax
Description
Tmax,ss of the total ingredient of AD-2101 and AD-2102
Time Frame
pre-dose to 24 hours
Title
Clearance
Description
CLss/F of the total ingredient of AD-2101 and AD-2102
Time Frame
pre-dose to 24 hours
Title
Bottom Plasma Concentration
Description
Cmin,ss of the total ingredient of AD-2101 and AD-2102
Time Frame
pre-dose to 24 hours
Title
Number of participants with adverse events
Description
Incidence rate of adverse events
Time Frame
From Day 1 up to Day 66

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male between 19 and 50 years of age at the time of screening Weight above 50 kg and body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2 Exclusion Criteria: Clinically significant disease or history of clinically significant disease such as cardiovascular, respiratory, liver, kidney, digestive, hematologic/oncologic, endocrine, immunologic, urinary, psychiatric Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery A person who has a history of drug abuse AST, ALT, Total bilirubin values over than 2 times of UNL at screening Creatinine clearance under 80mL/min
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
HyeWon Chung
Organizational Affiliation
Korea University Guro Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

We'll reach out to this number within 24 hrs